NEW YORK (GenomeWeb) – MDxHealth announced today that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to Qiagen for use in its QIAsure assay, a CE-marked test for use in differentiating patients' risk of developing cervical cancer.

Under the terms of the agreement, MDxHealth will receive a signing fee plus royalties from future test sales utilizing the technology.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.